Table 1.
Commercial marine-derived compounds.
| Compound Name | Marine Organism | Chemical Class | Molecular Target (Target Hallmarks) |
Cancer Type | References |
|---|---|---|---|---|---|
| Crytarabine | Sponge | Nucleoside | DNA polymerase | Leukemia | [8,9,10,11] |
| Eribulin mesylate | Sponge | Macrolide | Microtubules | Metastatic breast cancer | [8,9,12,13] |
| Brentuximab vedotin | Mollusk/ cyanobacterium |
ADC (MMAE) |
CD30 and microtubules | Anaplastic large T-cell systemic malignant lymphoma, Hodgkin disease | [8,14,15] |
| Trabectedin | Tunicate | Alkaloid | Minor groove of DNA | Soft tissue sarcoma and ovarian cancer | [8,16,17,18] |
| Plitidepsin | Tunicate | Dipsipetide | eEF1A2 | Multiple myeloma, leukemia, lymphoma | [8,19,20,21,22] |
| Polatuzumab vedotin | Mollusk/cyanobacterium | ADC (MMAF) |
CD76b and microtubules | Non-Hodgkin lymphoma, chronic lymphocytic leukemia, lymphoma, B-cell lymphoma, folicular | [8,23,24] |
| Enfortumab vedotin | Mollusk/cyanobacterium | ADC (MMAE) |
Nectin-4 | Metastatic urothelial cancer | [8,25] |
| Belantamab mafodotin | Mollusk/cyanobacterium | ADC (MMAF) |
BCMA | Relapsed/refractory multiple myeloma |
[8,26] |
| Lurbinectedin | Tunicate | Alkaloid | RNA polymerase II | Metastatic small-cell lung cancer |
[8,27,28,29,30] |